Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis of cohort studies

Back

ESC Professional Premium Access

Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis of cohort studies

Session: Coronary artery disease - Pharmacotherapy 3

Topic: Pharmacotherapy

Speaker: Mr S. Soulaidopoulos (Athens, GR)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Mr Stergios Soulaidopoulos

Hippokration General Hospital, Athens (Greece)

0 follower

6 more presentations in this session

Effect of exercise-based cardiac rehabilitation on the ischemic threshold in patients with high-risk ischemic heart disease

Speaker: Doctor J. Lara Vargas (Ciudad de Mexico, MX)

Access

Abstract

Slides

Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study

Speaker: Doctor A. Spirito (New York, US)

Access

Abstract

Slides

Low dose rivaroxaban therapy in aspirin allergic patients undergoing percutaneous coronary intervention

Speaker: Doctor S. Manjooran (London, GB)

Access

Abstract

Slides

Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial

Speaker: Doctor S. Patel (Boston, US)

Access

Abstract

Slides

Thrombin generation and endothelial progenitor cell function among patients with acute myocardial infarction treated with prasugrel versus ticagrelor

Speaker: Doctor M. Wiessman (Dallas, US)

Access

Abstract

Slides

Access the full session

Coronary artery disease - Pharmacotherapy 3

Speakers: Mr S. Soulaidopoulos, Doctor J. Lara Vargas, Doctor A. Spirito, Doctor S. Manjooran, Doctor S. Patel...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources